The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe

Area of Science:

• Infectious Diseases
• Clinical Trials Methodology
• Medical Research

Background:

• Staphylococcus aureus bloodstream (SAB) infection is a severe condition with high mortality (15%-30%).
• Limited clinical trial data exists for SAB treatments due to recruitment challenges.
• Traditional trial methods hinder large-scale SAB research.

Purpose of the Study:

• To present the rationale and framework for an adaptive platform trial for SAB infections.
• To introduce the design of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial.
• To demonstrate an efficient model for conducting clinical trials in infectious diseases.

Main Methods:

• Implementation of an adaptive platform trial design.
• The Staphylococcus aureus Network Adaptive Platform (SNAP) trial framework enables multiple research questions.
• Multi-country patient enrollment initiated in 2022.

Main Results:

• The SNAP trial aims to enroll approximately 7000 participants.
• The adaptive platform design facilitates efficient data collection and analysis.
• This approach is designed to answer multiple research questions simultaneously.

Conclusions:

• The SNAP trial offers an innovative and efficient approach to studying SAB infections.
• Adaptive platform trials can overcome traditional limitations in infectious disease research.
• This model may serve as a template for future clinical trials in other infectious syndromes.